Demystifying the antiviral activity of the IgG3+ antibody response

  • Funded by National Institutes of Health (NIH)
  • Total publications:18 publications

Grant number: 3R37AI080289-11S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $391,727
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    MASSACHUSETTS GENERAL HOSPITAL
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Since 2002, several coronaviruses have emerged able to cause severe respiratory disease, however no vaccineis available to prevent these rapidly spreading pathogens. Vaccine design has specifically lagged due to our lackof understanding of the correlates of immunity against these pathogens. Both cellular and humoral immuneresponses have been implicated in resolution of disease, but to date only the passive transfer of antibodies hasbeen shown to confer complete protection in mice. Interestingly, the transfer of both "neutralizing" and non-neutralizing antibodies have shown protective efficacy, highlighting the role of multiple humoral mechanisms inlimiting viral infection/spread. The precise mechanism of action of these antibodies that have the most profoundimpact on limiting disease is currently unclear, but if elucidated could provide critical insights for the developmentof effective vaccines against COVID-19 and other coronaviruses. Thus, here we aim to take a systematicapproach to dissect and define both the polyclonal and monoclonal mechanisms by which antibodies conferprotection against COVID-19. Specifically, samples from DNA- and adenovirus 26 (Ad26)- COVID-19 Spikeprotein (S) immunized animals, that will be challenged with COVID-19, will be comprehensively profiled usingSystems Serology, to define the functional humoral immune responses linked to protection from infection/diseasein mice, ferrets, and macaques. Machine learning modeling will be employed to discern key immune responsefeatures that translate usefully across these diverse animal contexts. Coupled to a novel systems-Fc-engineeringapproach, the COVID-19 CR3022 monoclonal antibody will be engineered to specifically define the Fc-effectorfunctions that provide the greatest impact on limiting disease. Collectively, these studies will not only definecorrelates of immunity across vaccines and species, but also provide mechanistic insights into the precisemechanisms by which antibodies may confer protection in the context of future vaccines.

Publicationslinked via Europe PMC

Last Updated:40 minutes ago

View all publications at Europe PMC

Distinct cytokine profiles in late pregnancy in Ugandan people with HIV.

Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern.

Humoral profiling of pediatric patients with cancer reveals robust immunity following anti-SARS-CoV-2 vaccination superior to natural infection.

Altered Maternal Antibody Profiles in Women With Human Immunodeficiency Virus Drive Changes in Transplacental Antibody Transfer.

Selective transfer of maternal antibodies in preterm and fullterm children.

Functional Compartmentalization of Antibodies in the Central Nervous System During Chronic HIV Infection.

Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.

The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design.

Trends in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Seroprevalence in Massachusetts Estimated from Newborn Screening Specimens.